Combination of TRC105 and Avastin did not improve the median progression free survival versus single agent Avastin in recurrent glioblastoma patients Combination was associated with a non-significant increase in overall survival SAN DIEGO, Feb. 09, 2017 — TRACON Pharmaceuticals , a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today reported top-line results from a randomized Phase 2 clinical trial of TRC105 in recurrent glioblastoma funded and conducted by the Clinical Therapy Evaluation Program of the National Cancer Institute .